Home' Australian Pharmacist : Australian Pharmacist October 2012 Contents Australian Pharmacist October 2012 I ©Pharmaceutical Society of Australia Ltd. 831
New Sustagen® OptimumTM
New Sustagen® OptimumTM tastes great and provides complete
nutrition so it can be used as a supplement to dietary intake during
times when a person is unable to meet their nutrient requirements,
such as poor appetite or illness.
It contains a unique combination of four
ingredients which act to support digestive
health, immunity and help maintain muscle
mass. These ingredients are high quality
protein, pre and probiotics as well as
antioxidants C & E.
It also contains 27 essential vitamins, is gluten
free, low in lactose and has a low GI.
Sustagen® OptimumTM is available from your
For more information on Sustagen® Optimum
Sustagen® OptimumTM is a Food for Special
Medical Purposes and is specifically formulated
for medical conditions where nutritional needs
cannot be met through diet modification
alone. Must be used under the supervision of a
healthcare professional. Suitable for use as a sole source of nutrition.
® Reg. Trademark of Société des Produits Nestlé S.A.
Nestlé Healthcare Nutrition, a division of Nestlé Australia Ltd, 20-24 Howleys Road, Notting Hill VIC
3168, Australia. For more information call 1800 671 628. For healthcare professional use only.
OCEANIA UNIVERSITY OF MEDICINE
NOW INTERNATIONALLY ACCREDITED
For more information visit www.oceaniamed.org or 1300 665 343
You're smart and successful... but you want more.
You know the science. Now get the clinical skills to become a physician.
No need to uproot family and move from friends and support systems
Continue working during first two years
-- OUM graduates are eligible to sit for the AMC exam
-- New classes begin every January and August.
BPharm to MBBS
1. Victoza Product Information. Novo Nordisk. 20 Jun 2011
2. Nauck M, Frid A, Hermansen K, et al. for the LEAD-2 Study
Group. Efficacy and safety comparison of liraglutide,
glimepiride, and placebo, all in combination with metformin,
in type 2 diabetes: the LEAD (liraglutide effect and action in
diabetes)-2 study. Diabetes Care 2009;32(1):84--90.
3. Internal analysis based on IMS Midas data, Feb 2012. Data on
file. Novo Nordisk A/S, Bagsværd, Denmark. Please contact
Novo Nordisk for additional information.
4. Pratley RE, Nauck M, Bailey T, et al. for the 1860-LIRA-DPP-4-
Study Group. Liraglutide version sitagliptin for patients with
type 2 diabetes who did not have adequate glycaemic control
with metformin: a 26-week, randomised, parallel-group, open-
label trial. Lancet 2010;375(9724):1447--56.
5. Pratley R, Nauck M, Bailey T, et al. for the 1860-LIRA-DPP-
4-Study Group. One year of liraglutide treatment offers
sustained and more effective glycaemic control and weight
reduction compared with sitagliptin, both in combination with
metformin, in patients with type 2 diabetes: a randomised,
parallel-group, open-label trial. The International Journal of
Clinical Practice. 2011;65(4):397-07
system. Which it
says is the rst
monitoring device to include a mealtime
(bolus) insulin calculator with a touch
screen interface. The FreeStyle InsuLinx
system also o ers user-friendly features,
including an automated logbook and
USB connectivity for plug-and-play
reports via the new FreeStyle Auto-
Assist data management software. The
FreeStyle InsuLinx mealtime (bolus)
insulin calculator feature is designed to
help people diagnosed with diabetes
accurately calculate a suggested
dose of rapid-acting insulin that can
help maintain appropriate blood
glucose levels, recommended by a
The FreeStyle InsuLinx system is
compatible with FreeStyle Lite blood
glucose test strips, which require
no coding and are designed to o er
easier blood application. It is only
available through diabetes healthcare
professionals and FreeStyle Lite test
strips are available for sale at pharmacies
throughout Australia. More information
on the FreeStyle InsuLinx blood glucose
monitoring system is available at: www.
Links Archive Australian Pharmacist September 2012 Australian Pharmacist November 2012 Navigation Previous Page Next Page